Search for dialysis centres here

Find a centre Log in to explore the world's most comprehensive database of dialysis centres for free!

Jobs in dialysis

dialysis.team.logo.small.000 Professional dialysis recruitment 

 

Dialysis industry news

Stories from the dialysis comunity across the globe.
Study finds significantly higher rate of untreated kidney failure ... - EurekAlert (press release) PDF Print
EurekAlert (press release)
... kidney function, and clinical outcomes have reported that elderly patients are less likely to develop end-stage renal disease (ESRD) compared with younger

...
 
Study finds significantly higher rate of untreated kidney failure among older ... - EurekAlert (press release) PDF Print
EurekAlert (press release)
"Studies of the association among age, kidney function, and clinical outcomes have reported that elderly patients are less likely to develop end-stage renal disease (ESRD) compared with younger patients and are more likely to die than to progress to

...
 
Research and Markets: Saudi Arabia Nephrology and Urology ... - Business Wire (press release) PDF Print

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7ptrvw/saudi_arabia_nephr) has announced the addition of GlobalData's new report "Saudi Arabia Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and Lithotripters" to their offering.

“Saudi Arabia Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and Lithotripters”

GlobalData's new report, Saudi Arabia Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and Lithotripters provides key market data on the Saudi Arabia Nephrology and Urology Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within three market categories - Incontinence Devices, Lithotripters and Renal Dialysis Equipment. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

Scope

- Market size and company share data for Nephrology and Urology Devices market categories - Incontinence Devices, Lithotripters and Renal Dialysis Equipment.

- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within three market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.

- 2011 company shares and distribution shares data for each of the three market categories.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.

- Develop market-entry and market expansion strategies.

- Design competition strategies by identifying who-stands-where in the Saudi Arabia Nephrology and Urology Devices competitive landscape.

- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.

Companies Mentioned

- Fresenius Medical Care AG & Co. KGaA

- Gambro AB

- Baxter International Inc.

- Dornier MedTech GmbH

- B. Braun Melsungen AG

- Siemens Healthcare

- NIPRO CORPORATION

- Svenska Cellulosa Aktiebolaget SCA

- HARTMANN GROUP

- Medline Industries, Inc.

- Kimberly-Clark Corporation

- STORZ MEDICAL AG

- First Quality Enterprises, Inc.

- Covidien plc

- C. R. Bard, Inc.

For more information visit http://www.researchandmarkets.com/research/7ptrvw/saudi_arabia_nephr

Source: GlobalData

...
 
Alarming increase in hypertension in US children - TheHeart.Org PDF Print
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

image Get 30 days of free access to heartwire news

...
 
Life on MARS: Emory Offers Lifesaving Liver Dialysis System for ... - Houston Chronicle PDF Print

Emory one of only five health centers nationwide to offer Molecular Adsorbents Recirculating System (MARS), a liver dialysis system approved by the U.S. Food and Drug Administration (FDA) to treat select patients with acute liver failure due to drugs or toxins.

Atlanta, GA (PRWEB) June 19, 2012

For many patients with acute liver failure, the only hope for treatment is a liver transplant. With transplant, waiting for an organ to become available can take a long time – time the patient does not have.

Emory is only one of five centers in the U.S. and the only one in the Southeast to offer the Molecular Adsorbents Recirculating System (MARS), a liver dialysis system recently approved by the U.S. Food and Drug Administration (FDA) to treat select patients with acute liver failure due to drugs or toxins. MARS can be used either as a bridge to transplant or spontaneous recovery, and highlights Emory’s institutional commitment to providing comprehensive, state-of-the-art liver critical care.

Says transplant hepatologist and intensivist Ram Subramanian, assistant professor at Emory University School of Medicine, “We have long had kidney dialysis to stabilize patients in renal failure, but until now, we have not had a corresponding method of treatment for patients in acute liver failure. MARS is a potential game changer for patients who either don’t qualify for transplant or who don’t have the time that is critical to wait for a liver transplant.”

Acute liver failure does not allow patients to clear certain toxins from their systems. The MARS system works by drawing blood from patients and cleansing it with a solution containing albumin. Albumin is produced by healthy livers and binds to certain medications and other bodily substances to transports them throughout the body while protecting the body from their toxic effects. This cleansed blood is returned to the patient’s circulatory system to attract more toxins.

MARS is the only FDA approved treatment of acute liver failure, but is currently under clinical trial investigation to treat forms of chronic liver illness.

“Several studies in Europe have demonstrated that MARS is effective in treating chronic liver failure as well,” says Subramanian. “My hope is that it becomes another tool for us in offering hope to patients who are dealing with all kinds of liver failure.”

Learn more about the MARS liver dialysis system in a video interview with Ram Subramanian, MD.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/6/prweb9615939.htm

...
 
More Articles...
<< Start < Prev 541 542 543 544 545 546 547 548 549 550 Next > End >>

Page 548 of 4210
Share |

Dialysis travel

Dialysis information

Global Dialysis

Copyright © 2026 Global Dialysis. All Rights Reserved.